Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01088295 · ClinicalTrials.gov registry record · Phase 2
HIV and Fat Accumulation
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01088295 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 35 participants.
The verdict
NCT01088295, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a research study to see whether fat accumulation either under the skin or in the body's organs, for example, the liver, improves in men and women who take a drug called telmisartan. The investigators will be looking at how the amount of fat in the body changes when HIV-positive persons on effective anti-HIV therapy take telmisartan. The investigators will be using a CT scan to make this comparison. Telmisartan is not an HIV medication. It is a medication used to treat blood pressure, but has been shown to decrease fat in the organs in people both with and without high blood pressure. The study involves 8 visits over a period of about 24 weeks.
Interventions
- DRUG Telmisartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01088295
The ClinicalTrials.gov registry entry for NCT01088295 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telmisartan is the first listed.
NCT01088295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01088295 about?
NCT01088295 is a clinical study titled "HIV and Fat Accumulation". This is a research study to see whether fat accumulation either under the skin or in the body's organs, for example, the liver, improves in men and women who take a drug called telmisartan. The investigators will be looking at how the amount of fat in the body changes when HIV-positive persons on ef...
What is the current status of trial NCT01088295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2010-05. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01088295?
The interventions under investigation include: Telmisartan (DRUG).
Who is sponsoring clinical trial NCT01088295?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.